We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · September 27, 2021

Long-Term Effects of Dapagliflozin Plus Saxagliptin Versus Glimepiride on a Background of Metformin in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: results of a 104-week extension to a 52-week randomised, phase 3 study and liver fat MRI sub-study
Diabetes Obes Metab 2021 Sep 13;[EPub Ahead of Print], JP Frías, J Maaske, L Suchower, L Johansson, PD Hockings, N Iqbal, JPH Wilding

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading